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South AfricaBackground: RV144 is to date the only HIV vaccine trial to demonstrate efficacy, albeit rapidly waning
over time. The HVTN 702 trial is currently evaluating in South Africa a similar vaccine formulation to that
of RV144 for subtype C HIV with additional boosters (pox-protein regimen). Using a detailed stochastic
individual-based network model of disease transmission calibrated to the HIV epidemic, we investigate
population-level impact and maximum cost of an HIV vaccine to remain cost-effective.
Methods: Consistent with the original pox-protein regimen, we model a primary series of five vaccina-
tions meeting the goal of 50% cumulative efficacy 24 months after the first dose and include two-
yearly boosters that maintain durable efficacy over 10 years. We simulate vaccination programs in
South Africa starting in 2027 under various vaccine targeting and HIV treatment and prevention assump-
tions.
Results: Our analysis shows that this partially effective vaccine could prevent, at catch-up vaccination
with 60% coverage, up to 941,000 (15.6%) new infections between 2027 and 2047 assuming current
trends of antiretroviral treatment. An impact of up to 697,000 (11.5%) infections prevented could be
achieved by targeting age cohorts of highest incidence. Economic evaluation indicates that, if treatment
scale-up was achieved, vaccination could be cost-effective at a total cost of less than $385 and $62 per 10-
year series (cost-effectiveness thresholds of $5,691 and $750).
Conclusions: While a partially effective, rapidly waning vaccine could help to prevent HIV infections, it
will not eliminate HIV as a public health priority in sub-Saharan Africa. Vaccination is expected to be
most effective under targeted delivery to age groups of highest HIV incidence. Awaiting results of trial,
the introduction of vaccination should go in parallel with continued innovation in HIV prevention, includ-
ing studies to determine the costs of delivery and feasibility and further research into products with
greater efficacy and durability.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
With an estimated global prevalence of 36.7 million infected
people as of 2015, HIV remains a public health priority in manycountries [1]. Despite continued efforts to scale up treatment,
resulting in 18.2 million people receiving antiretroviral therapy
[2], an estimated 2.1 million people (including 150,000 children)
were newly infected in 2015. Reaching the ambitious goal of 90-
90-90 by 2020 (90% of people infected with HIV should know their
status, with 90% of people diagnosed with HIV infection to be
receiving antiretroviral treatment and 90% of people receiving
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substantial treatment gap but also prevent new infections. How-
ever, a recent modeling study including 127 different countries
suggests that the majority of countries under consideration
(including South Africa) is unlikely to meet the 90-90-90 target
[3]. This, and the difficulty in rolling out existing methods of HIV
prevention (such as medical male circumcision, and oral pre-
exposure prophylaxis) to key populations, highlight the need for
a preventative vaccine [4].
October of 2016 marked the launch of the first trial in seven
years to test the preventative efficacy of an HIV vaccine in
humans. HVTN 702 is a phase 2b/3 trial [5], supported by the
Pox-Protein Public-Private Partnership (P5) [6]. It is testing a
modified version of the only HIV vaccine to date that has shown
evidence of efficacy in humans. In 2009, RV144 showed partial
reduction in HIV acquisition among community-based, predomi-
nantly heterosexual participants in Thailand using a modified
intent-to-treat analysis (vaccine efficacy of 31.2% (95% CI: 1.1–
52.1%) at month 42 after the first vaccination) [7]. Though the
efficacy of the vaccine appeared to be greatest shortly after the
last dose and then waned rapidly, a recent follow-up study
[8,9] in which a subset of RV144 participants was re-vaccinated
up to six years after enrollment reported immune memory
responses two weeks after re-vaccination, offering hope that an
extended immunization schedule could potentially increase vac-
cine durability.
The ongoing HVTN 702 study is a multi-site, randomized,
double-blinded, placebo-controlled clinical trial designed to test
a regimen adapted to HIV Clade C exposed populations in South
Africa. In addition to the six-month series tested in RV144, its orig-
inal protocol comprises a booster dose at month 12, as well as a
change in adjuvant (from alum to MF59) to the gp120 protein com-
ponent of the vaccine, and a recently amended 18-month booster
dose. Preliminary results of HVTN 100 [10], a small-scale clinical
trial evaluating the ALVAC-HIV (vCP2438) + Bivalent Subtype C
gp120/MF59 (short: ALVAC-HIV-C+gp120) vaccine, suggest good
safety, tolerability, and immunogenicity of the modified product
and regimen.
If this or an improved pox-protein HIV vaccine regimen is pro-
ven to be sufficiently efficacious and licensable, timely and effi-
cient scale-up will require an evidence-based vaccine access plan
that defines expectations and outlines commitments essential to
making a licensed vaccine available to priority populations in
South Africa and potentially beyond. To inform the development
of an access plan, the P5 Global Access Committee (short: GAC,
comprised of representatives from the Bill & Melinda Gates Foun-
dation, National Institutes of Health (DAIDS/NIAID), Sanofi Pasteur,
GlaxoSmithKline and the South African Medical Research Council)
has engaged in a variety of preparatory analyses -including com-
missioning the modelling work detailed in this article- to identify
the populations that would benefit most from the vaccine. Here,
target populations for vaccination were solely defined based on
age and sex, although other key populations (e.g. commercial sex
workers) could have similar benefits from vaccination should the
product prove efficacious.
In South Africa, HIV incidence varies considerably by age and
sex. The highest HIV incidence rates are observed in young women
aged 15–24. In 2012, the estimated incidence in this age group was
2.54% per year (95% 2.04–3.04%), which is five times the rate of HIV
incidence in young men aged 15–24 [11,12]. Recent results from an
observational HIV study in rural KwaZulu-Natal suggest the high-
est risk of infection among women aged 18–28, and men aged
23–33 [13,14]. These epidemic patterns imply that prioritizing
high levels of vaccination among young women and a slightly older
age group of men would most efficiently reduce new HIV
infections.However, determining the optimal use of an HIV vaccine based
on age patterns of incidence has several complications. First, an
optimal vaccination schedule should account for any waning effi-
cacy, recommendations for booster dose frequency, and rate of
attrition from the recommended series of HIV vaccine doses. Sec-
ond, a licensed vaccine may take up to a decade before being
approved for widespread use in South Africa. In the interim,
nationally representative HIV epidemiologic patterns are likely to
change from current data, which dates back to 2012. Forecasting
changes in incidence patterns is needed to predict the likely impact
of implementation scenarios under consideration and design a rel-
evant and effective scale-up strategy. Finally, the patterns of HIV
transmission must be accounted for in order to fully capture the
potential population-level impact of a vaccine. Effective vaccina-
tion will prevent HIV infections not only in the direct recipients,
but also in their sexual partners within the contact network.
Several modeling studies [3,15–24] have estimated impact and
cost-effectiveness of an RV144-like vaccine, but all have assumed
either a constant level of efficacy or exponentially waning immu-
nity after a single course of vaccination. In addition to bridging
these gaps, the present work offers additional improvements such
as application of an age-structured HIV network model, more real-
istic date of vaccine introduction, and complex booster schedules.
Here, we estimate the impact of a 10-year vaccine regimen (pri-
mary series and boosters) within a 20-year vaccination program
on the HIV epidemic in South Africa using an individual-based net-
work model of HIV transmission structured by age, sex and risk.
We model the efficacy profile associated with the 5-dose regimen
following the original HVTN 702 protocol and include possible
booster doses following the primary series (beginning at
36 months from the first vaccination). The present analysis evalu-
ates and compares the impact and cost-effectiveness of implemen-
tation strategies initiating HIV vaccination based on targeted age
groups, coverage goals, booster attrition, roll-out, HIV treatment
scale-up, and oral pre-exposure prophylaxis (PrEP) availability.
Results from the present modelling analysis will help to inform
ongoing vaccine access planning elements, including priority pop-
ulations for whom the pox-protein HIV vaccine would be expected
to have the greatest and/or most efficient public health impact.
2. Methods
We developed an agent-based model of the South African pop-
ulation to forecast HIV infections, disability-adjusted life-years
(DALYs), and healthcare costs from a government payer perspec-
tive over a 30-year time horizon, from year 2018 to 2047. As com-
pared to a reference case with no HIV vaccine, we evaluate
implementation of strategies for initiation of HIV vaccination.
Model set-up and calibration. We modified EMOD-HIV v2.5,
an age-stratified and individual-based network model of HIV of
South Africa, to incorporate HIV vaccination according to pox-
protein HIV vaccine regimens (such as the regimen currently being
tested in HVTN 702). Because EMOD is an individual-based model,
interventions such as a time-varying course of vaccine efficacy can
be applied to each individual according to his or her own timing of
vaccination and adherence to the booster series. This renders the
model well suited for a nuanced analysis of the anticipated time-
dependent efficacy of the pox-protein HIV vaccine regimen.
To ensure that our analysis reflected the realities of the HIV epi-
demic and the health system in South Africa, we iteratively
engaged South African government, academic and community
stakeholders through one-on-one interviews, a vaccine access
planning summit and a public health impact modelling workshop
during which preliminary results of this work were presented
and discussed. This stakeholder engagement process helped us
understand perspectives on the future HIV prevention landscape,
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and the economic factors that will influence vaccine access, all of
which were incorporated into our analysis and considerations.
The parameters, model input values, sources, projections, and
sensitivities of the epidemic projection without vaccine, used as
the reference group for comparison, have been described previ-
ously [25–27]. A detailed model description, user tutorials, model
installer, and source code are available for download at http://id-
mod.org/software.
For detailed information on the model set-up, calibration and
baseline assumptions on HIV treatment and prevention other than
vaccine we refer to the Supplementary Material.
HIV Vaccine Efficacy. We incorporated a parametric model of
time-dependent vaccine efficacy that was hypothesized for the
pox-protein regimen based on results from RV144. We included
the time series of efficacy associated with each dose administered
during the study and possible booster doses beyond the 24-month
duration of the first stage of the study. The original pox-protein
dosing schedule administered a series of five immunizations over
12 months (the 18-month dose recently amended to the protocol
was not modeled here). ALVAC-HIV-C was administered at months
0 and 1, followed by ALVAC-HIV-C+gp120 at months 3 and 6, and
ALVAC-HIV-C+gp120 dose was administered at month 12 (supple-
mentary to RV144 schedule). Time-dependent vaccine efficacy was
interpreted as a per exposure reduction in the probability of acqui-
sition parameterized by an impulse and exponential decay model.
TimeDependentVaccineEfficacyðtÞ :¼
X
i2Schedule;i6t
ðai þ biÞexðtiþdÞ
where ai is the efficacy increase of immunization with ALVAC-HIV-
C, bi is efficacy increase after ALVAC-HIV-C+gp120 immunization,x
is the efficacy decay rate per month and d is the delay between
immunization and initiation of protective effect in months.
Assuming uniformly distributed exposure over a given time
span in the trial, we calculated the cumulative vaccine efficacy
(corresponding to the efficacy estimate from the trial) as the area
under the curve of the instantaneous vaccine efficacy rescaled by
the length of the time span.
VaccineEfficacyðtÞ :¼ 1
t
Z t
0
TimeDependentVaccineEfficacyðsÞds
In anticipation of efficacy results for HVTN 702, we modeled time-
dependent vaccine efficacy based on results from statistical models
[28] for RV144 study outcomes using a point-estimate of 58%
shortly after the month 6 vaccination, and cumulative efficacy of
31.2% over 42 months. We adjusted the parameters of the efficacy
function such that the cumulative vaccine efficacy over 24 months
after the first dose is 50% (corresponding to the goal set by the
P5) and obtained values ai ¼ 0:08; bi ¼ 0:34;x ¼ 0:065 and d ¼ 0:1.
Booster Schedule and Efficacy. For the purpose of model pro-
jections beyond the primary trial endpoint, we also implemented
up to four two-yearly boosters starting at month 36 with fixed
attrition rates of 0, 20 or 50% per booster to cover a total of 10 years
of vaccine efficacy. We assumed booster efficacy to follow the same
parameterization as ALVAC-HIV-C + gp120 doses from the primary
immunization series during the first 12 months. Booster eligibility
depended on having received the primary immunization series or
the booster previously. Missing a booster resulted in loss of eligi-
bility for subsequent boosters. Individuals who tested HIV positive
were not eligible for future boosters, and we did not add HIV test-
ing to the cost. We assumed that four booster doses after the pri-
mary first-year series were necessary to confer one decade of
protection. For catch-up vaccination scenarios, booster eligibility
was limited by the age range of the vaccinee.Vaccination Strategies for Evaluation. Based on consultations
with the P5 GAC, we evaluated 30 implementation strategies for
HIV vaccine targeting and implementation. Strategies included a
wide range of age- and gender-specific targeting scenarios at low
(30%), medium (50%) and high (80%) coverage using two distinct
roll-out approaches starting in 2027, the earliest realistic date of
introduction: Cohort vaccination, aiming for immunization and
follow-up boosting of a pre-specified proportion (coverage) of indi-
viduals at a particular target age every year over the period between
2027 and 2047 (Table S1), and catch-up vaccination scenarios
(Table S2) were implemented for individuals within a pre-specified
age range starting in 2027 with a linearly increasing coverage to
reach the ramp-up coverage in 2032, followed by cohort-like vacci-
nation from 2032 onwards for individuals aging into the target range
at a maintenance coverage which was 20% higher than the ramp-up
coverage. For both roll-out scenarios, we assumed no coverage attri-
tion for the primary immunization series. Eligibility for vaccination
was assumed to be independent of PrEP usage, and individuals hav-
ing tested positive for HIV were not eligible for vaccination.
ART and PrEP Scale-Up Scenarios. To account for uncertainty
in predicting the next decade of the HIV epidemic, we varied the
scale-up of treatment in terms of ART and oral PrEP coverage and
considered three scenarios. In the most pessimistic scenario (Sta-
tus Quo without PrEP), we stipulated that guideline changes have
no impact on ART initiation. We excluded any use of oral PrEP.
These assumptions were consistent with the 60% ART coverage
under current guidelines assumed in the HIV/TB Investment Case
Report for South Africa [29] and reflect to some extent recent pes-
simistic results on treatment linkage and scale-up in South African
settings [3,30]. A moderately optimistic scenario (‘Status Quo with
PrEP’) maintained ART linkage assumptions of ‘Status Quo without
PrEP’, but assumed reaching oral PrEP coverage of 30% by 2027 and
maintained this level for high risk men and women under 30 years
of age. In the most optimistic scenario (‘Fast Track with PrEP’), we
kept the same PrEP coverage as in scenario ‘Status Quo with PrEP’,
increased testing and linkage to ART and decreased lost-to-follow-
up which results in close to 90% ART coverage in 2047. We did not
incorporate behavior change into the ‘Fast Track with PrEP’ scenar-
io, as detailed in the Fast Track UNAIDS goals [31].
Metrics for population-level health impacts. Epidemic impact
was estimated in terms of the number of HIV infections prevented
over the period between 2027 and 2047, calculated as differences
between the total number of infections given a vaccination strategy
and the reference with no HIV vaccine, over the 20-year time period.
The fraction of cumulative infections prevented was calculated as the
ratio of new infections averted to the number of new infections accu-
mulated between 2027 and 2047 in the reference case (covering thus
the period of vaccination). For each implementation policy strategy
evaluated, we sampled with replacement from 50 simulation results
(corresponding to the 50 most likely parameter sets obtained from
the calibration process,see Supplementary Material) to obtain boot-
strap mean estimates. The 2:5 and 97:5 percentiles of the sample
mean distribution formed the lower and upper bounds of the boot-
strapped confidence intervals [32]. This accounts for parameter
uncertainty within a neighborhood where likelihood is maximal.
We report infections prevented by rounding to thousands.
We also estimated the number needed to vaccinate (NNV) per
infection prevented, defined as the ratio of the average number of
vaccine regimens distributed to the average number of new infec-
tions prevented. The number of vaccine regimens distributed was
defined as the number of primary series completed. Health impact
was summarized in disability-adjusted life years (DALYs), calculated
as the present discounted value of years of healthy life lost to disabil-
ity and years of life lost to premature death over a 20-year horizon of
vaccination [33]. Disability weights for HIV health states differed
by CD4-count category (Table 1). DALYs averted were calculated by
Table 1
Parameters for health impact and economic evaluation analysis.
Healthcare costs, adjusted to 2015 US$
Cost of vaccine Wholesale acquisition cost of HIV vaccine product,
cost of delivery, implementation, distribution, clinic
visits, per regimen
Unknown
Cost of PrEP Average cost per person-year 287 US$ [16,29]
Drugs 172 US$
Visits, Testing, Labs 115 US$
HIV care cost Average cost per person-year 419 US$ [16]
ART drugs 197 US$
Labs 90 US$
Salaries 66 US$
Outpatient, others 66 US$
Health outcomes
Disability Weights for HIV,
given CD4-count
Unit disability weights per life year [34–36]
> 350 0.053
200 349 0.221
< 200 0.547
Other variables
CET Cost-effectiveness threshold
in 2015 US$/DALY averted
5,691 US$ South African GDP
per capita in 2015 [37]
750 US$ HIV/TB investment case,
Table 54 in [29]
C. Selinger et al. / Vaccine 37 (2019) 2258–2267 2261subtracting cumulative DALYs with vaccine from those without vac-
cine for each of the three treatment and prevention scale-up scenar-
ios. We measured health outcomes in DALYs to capture changes in
both the length and quality of life for individuals in the population.
DALYs were discounted 0, 3 or 5% annually.
Maximum Vaccine Costs. The launch price and implementa-
tion cost of an HIV vaccine in South Africa are unknown. Following
a value-based pricing framework for medicines [38–40], a thresh-
old analysis varied the vaccine cost parameter value to identify
potential maximum cost-effective HIV vaccine costs (including
both wholesale acquisition and implementation cost), as an aver-
age across persons receiving different numbers of doses.
Based on strategy-dependent changes in total discounted health-
care costs and DALYs, as compared to the reference with no vaccine,
we estimated the maximum vaccination cost level for a vaccination
strategy to be cost-effective. This cost level included both the ALVAC
and the protein component, as well as implementation cost (e.g. per-
sonnel cost of vaccine delivery, facility-level costs, supply-chain
management). Since we assumed complete primary series, wasted
doses could potentially originate only frommissed two-yearly boost-
ers. South Africa does not have an established cost-effectiveness
threshold per DALY-averted to determine value for money, although
some recent estimates are now available [29,41,42]. The cost-
effectiveness threshold should represent the opportunity costs of
committing scarce health system resources to an intervention [41].
To aid with interpretation, we assumed a threshold of 1x the 2015
gross domestic product (GDP) per capita in South Africa as a cost-
effectiveness threshold as well as a threshold of approximately 750
US$ per DALY averted, as determined by the South African HIV/TB
investment case study group (see Table 54 in [29]).
HIV Vaccine Price Thresholds. For a given nominal vaccinecost
and vaccination strategy, we calculated the net DALY burden rela-
tive to the no vaccine reference caseat a given cost-effectiveness
threshold (CET):
net DALY burdenðcostvaccineÞ :¼ DALYswith vaccine  DALYsno vaccineð Þ
þ costwith vaccineðART;PrEP;Vaccinatedð Þ  costno vaccineðART; PrEPÞf g=
CET
Cost and DALYs, accumulated between 2017 and 2047, were aver-
aged across stochastic replicates, treatment scale-up scenarios and
booster attrition levels, and discounted annually at a fixed rate of0, 3 or 5%. The strategy-specific maximum vaccine cost that remains
cost-effective was defined as the maximum regimen cost such that
net DALY burden would remain negative, indicating a reduction in
population burden of disease (i.e. health gain) from vaccine and
improvement in societal welfare. Bootstrapped confidence intervals
for vaccine cost were obtained by the same method as described
above in the section on population-level impact.
3. Results
3.1. Incidence given no HIV vaccine
Varying assumptions about linkage to and drop-out from ART
and uptake of oral PrEP between 2016 and the presumed start of
vaccination in 2027 results in distinct future ART coverage and
incidence estimates. For the scenarios ‘Status Quo without PrEP’,
‘Status Quo with PrEP’ and ‘Fast Track with PrEP’, the average per-
centage of HIV-diagnosed individuals on ART would be 56, 55 and
85% respectively in 2027, compared to 54% in 2016 (Fig. S2). Like-
wise, for the same scenarios, annual HIV incidence in women aged
15–49 is projected to decline from 1.6% in 2016 to 1.21% for ‘Status
Quo without PrEP’, 1.17% for ‘Status Quo with PrEP’, and 0.76% for
‘Fast Track with PrEP’ by the year 2027. During the same time per-
iod, annual HIV incidence in men aged 15 to 49 is projected to
decline from 0.9% to 0.7%, 0.68% and 0.41% respectively (Fig. 1).
The gender discrepancy in incidence is maintained, with a male-
to-female incidence ratio between 0.57 and 0.54 in 2027 regardless
of the scale-up assumptions. For a general population aged 15–49,
the average incidence rate in 2027 across all three scale-up and
prevention scenarios is projected to be 0.81%.
Without the vaccine, model projections predict an average of
0.84%, 0.76% and 0.48% annual HIV incidence in a general popula-
tion aged 15–49 by 2047 for ‘Status Quo without PrEP’, ‘Status
Quo with PrEP’ and ‘Fast Track with PrEP’ respectively. This indi-
cates that introduction of oral PrEP for high-risk groups starting
in 2016 will have a smaller impact on overall HIV incidence as
compared to ART scale-up.
3.2. Time-dependent and cumulative vaccine efficacy
Fitting the impulse and exponential decay model to known
time-dependent vaccine efficacy estimates [28] for the first six
Fig. 1. Averaged incidence rates projected under three different treatment and prevention scale-up scenarios starting in 2016, without vaccination: ‘Status Quo without PrEP’
in blue, ‘Status Quo with PrEP’ in red, ‘Fast Track with PrEP’ in green, and the average across all three scale-up scenarios in grey. (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
Fig. 2. Time-dependent vaccine efficacy (red) is modeled by a parametric impulse and exponential decay model. Cumulative vaccine efficacy at a given endpoint (green) is
interpreted as the area under the time-dependent vaccine efficacy curve (shaded red) normalized by the length of the considered time period. We first fit to RV144 point estimates
at month 6 and the 3 years endpoint of cumulative efficacy (red and green cross in the small panel). Then weadjusted parameters of the time-dependent vaccine efficacy curve to
the P5 regimen schedule such that the goal of 50% efficacy at the 24 month endpoint is met (green point). Dotted lines refer to time-dependent vaccine efficacy with continued
booster vaccination after month 24. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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such that the goal of 50% efficacy at the month 24 endpoint is met,
results in a time-dependent efficacy curve (Fig. 2, red curve) peak-
ing at 80% shortly after the additional month 12 booster. Exponen-
tial waning rates are estimated at 0.065 per month, and with each
dose of ALVAC-HIV-C+gp120, incremental efficacy increases by
34%. Two-yearly boosters starting at month 36 will sustain durabil-
ity with a maximum of 29.6% cumulative efficacy over one decade
of vaccination, whereas discontinuing boosters after the first-year
series yields a reduced cumulative efficacy of 14.8% (Fig. 2, green
curve). For the latter case, estimated efficacy of 40% at month 39
coincides with predictions from recently developed statistical
approaches using immune correlates of protection [43].3.3. Impact of targeting and durability
To determine vaccination age-targeting of highest impact, we
compare cohort vaccination at age 18 to age 15, with or without
a 5-year age off-set betweenmen and women (Fig. 3) at a relatively
high coverage of 80%, averaged across the treatment and preven-
tion scale-up scenarios (see Fig. S3 for 50% coverage outcomes).
Vaccine eligibility at 15 years of age with full booster retention
for one decade prevents between 321;000 (95% CI:
312;000 329;000) and 504;000 (95% CI: 494;000 516;000)
new infections over twenty years, assuming ‘Fast Track with PrEP’
and ‘Status Quo without PrEP’ respectively. This corresponds to
8:28% (95% CI: 8.11–8.45%) and 8:34% (95% CI: 8.17–8.52%) of
Fig. 3. Impact of cohort vaccination at 80% coverage for different treatment scale-up scenarios measured by average number of new infections (first row), percent of new
infections prevented (second row), and number needed to vaccinate (third row) between 2027 and 2047 at 50% vaccine efficacy and varying levels of booster attrition (0%,
20% and 50%). Average and 95% confidence intervals are relative to summary statistics across stochastic replicates.
C. Selinger et al. / Vaccine 37 (2019) 2258–2267 2263new infections prevented respectively. We note that the difference
in percent new infection prevented between the two scale-up sce-
narios is negligible, since the number of new infections in the
counter-factual (i.e. without vaccine) for ‘Fast Track with PrEP’ is
substantially lower than in the ‘Status Quo without PrEP’ scenario.
High booster attrition at 50% would decrease these numbers to
176;000 (95% CI: 168,000–185,000) and 309;000 (95% CI:
296,000–320,000) respectively.
A difference in vaccination age between men and women of
5 years provides additional benefit with up to 402;000 (95% CI:
392,000–412,000) and 642;000 (95% CI: 632,000–652,000) of
new infections prevented for the two scale-up scenarios respec-
tively. Missing 50% of booster would decrease the impact to
256;000 (95% CI: 247,000–265,000) and 434;000 (95% CI:
426,000–443,000) for vaccination assuming ‘Fast Track with PrEP’
and ‘Status Quo without PrEP’ respectively.
Further impact can be achieved by targeting 18-year-olds
resulting in 426;000 (95% CI: 416,000–435,000) and 604;000(95% CI: 593,000–615,000) infections prevented respectively at
0% booster attrition. Echoing the age difference in the peak of
HIV incidence, vaccinating 18-year-old women and 23-year-old
men would increase the impact to up to 501;000 (95% CI:
491,000–512,000) and 697;000 (95% CI: 687,000–707,000) infec-
tions prevented respectively, given full booster retention.
The impact of age off-setting and vaccination age is also high-
lighted by the number needed to vaccinate (NNV) to prevent a
new infection. When vaccinating at age 15 without versus with
age off-set the NNV decreases from 55:7 to 43:9 and from 34:6 to
27:0 respectively. Likewise, vaccinating 18-year-olds requires
41:0 and 28:5 NNV respectively, a five-year age off-setting would
decrease these numbers to 34:2 and 24:3 NNV. To illustrate the
importance of continued boosting for long-term impact, simulating
the latter scenario under 50% (instead of 0%) attrition after each
booster dose results in a rise to 45:4 and 32:7 NNV.
Catch-up vaccination appears to be particularly impactful, i.e.
by targeting age ranges between 15and 32 at the beginning of
Table 2
Economic evaluation.
Targeting Vaccine regimensa,d DALYs averteda,b Vaccine costc ART cost savinga,b
(coverage, gender, age) (in million) (in million) (in US$) (in million US$)
Fast Track with PrEP 50% men & women age 15 5.61 0.07 (0–0.16) 105 (0–236) 486.33
50% men age 20 & women age 15 5.57 0.18 (0.1–0.26) 272 (166–388) 1158.21
80% men & women age 15 8.69 0.19 (0.11–0.26) 176 (103–248) 1181.60
80% men age 20 & women age 15 8.64 0.19 (0.11–0.28) 186 (106–266) 1255.39
50% men & women age 18 5.55 0.21 (0.11–0.29) 307 (187–437) 1286.80
50% men age 23 & women age 18 5.48 0.26 (0.16–0.35) 383 (240–527) 1592.42
80% men & women age 18 8.60 0.29 (0.19–0.39) 277 (193–370) 1810.46
80% men age 23 & women age 18 8.50 0.37 (0.27–0.45) 354 (261–444) 2286.89
60% men & women age 15–32 15.52 0.74 (0.65–0.82) 361 (320–401) 4543.12
60% men & women age 18–35 15.14 0.77 (0.69–0.85) 385 (349–426) 4705.41
Status Quo without PrEP 50% men & women age 15 5.53 0.37 (0.24–0.49) 533 (352–724) 2176.25
50% men age 20 & women age 15 5.50 0.54 (0.41–0.67) 786 (613–968) 3192.02
80% men & women age 15 8.57 0.53 (0.4–0.68) 500 (371–617) 3177.77
80% men age 20 & women age 15 8.52 0.7 (0.56–0.83) 659 (541–782) 4158.92
50% men & women age 18 5.45 0.41 (0.27–0.54) 604 (394–807) 2448.40
50% men age 23 & women age 18 5.36 0.51 (0.36–0.66) 763 (556–989) 3022.80
80% men & women age 18 8.45 0.62 (0.5–0.74) 589 (481–689) 3700.01
80% men age 23 & women age 18 8.32 0.81 (0.68–0.95) 787 (657–915) 4833.93
60% men & women age 15–32 15.15 1.45 (1.32–1.59) 718 (652–795) 8634.57
60% men & women age 18–35 14.69 1.47 (1.33–1.6) 749 (679–810) 8665.38
All numbers are averaged over 50 simulations, with full booster retention. 95% confidence intervals, if provided, are in parentheses.
a Cumulative sum 2027–2047.
b 5% annual discount starting in 2018.
c Maximum vaccine cost at a cost-effectiveness threshold of 1x GDP. This takes ART cost saving into account, it is not an additional benefit.
d Number of primary series of five vaccinations administered.
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80% thereafter, the number of new infections prevented increases
from 321;000 to 689;000 (95%CI: 679,000–699,000) (or 18:1%
(95%CI: 17.9–18.3%)) and from 504;000 to 941;000 (95%CI:
932,000–951,000) (or 15:6% (95%CI: 15.5–15.7%)) for ‘Fast Track
with PrEP’ and ‘Status Quo without PrEP’ scenarios respectively
(Fig. S4). Shifting the age range for catch-up vaccination to 18 to
35 years would have a similar impact of 695;000 (95%CI:
686,000–704,000) (or 18:3% (95%CI: 18.1–18.5%)) and 935; 000
(95%CI: 924;000 945;000) (or 15:5% (95%CI: 15.3–15.6%)) infec-
tions prevented respectively.
Cohort vaccination at 80% or 50% coverage would require
approximately 8:4 million or 5:5 million vaccine regimens over
20 years (Table 2). Catch-up vaccination would require substan-
tially more vaccine regimens in the early years of the vaccination
program, with reduced demand in later years (Fig. S4), totaling
15:2 million regimens over 20 years (Table 2). Because of limited
durability of vaccine efficacy, the fraction of the sexually active
population with partial protection remains small, in spite of high
coverage for target populations (Fig. S6).3.4. Vaccination cost thresholds
For economic evaluation of vaccine cost per regimen (including
delivery and implementation costs), we calculated the maximum
cost at which vaccination would remain cost-effective, referred
to as maximum vaccine cost in what follows. Cost-effectiveness
thresholds are relative to the 2015 gross domestic product (GDP)
of South Africa of 5,691 US$ per capita [24]. Since future HIV inci-
dence and booster attrition rates remain highly speculative, cost
and DALYs estimates are averaged across simulations with 0%
booster attrition, such that the resulting vaccine cost is an upper
bound in terms of durability. For cohort vaccination at 80% cover-
age with a cost-effectiveness threshold of 1x per-capita GDP per
DALY averted, the average maximum vaccine cost (for both vaccine
product and implementation of a 10-year vaccine series) ranges
from 176 US$ (95% CI: 103 US$–248 US$) to 354 US$ (95% CI:
261 US$–444 US$) (Table 2) in ‘Fast Track with PrEP’ scenarios.Under the same scale-up assumption, at 60% catch-up vaccination,
maximum cost-effective vaccine cost ranges from 361 US$ (95% CI:
320 US$–401 US$) to 385 US$ (95% CI: 349 US$–426 US$).
Although the catch-up strategy requires substantially more vac-
cine regimens, it also offers higher ART cost savings (Table 2). For
the ‘Status Quo without PrEP’ scenario, maximum vaccine cost
would more than double, ranging between 500 US$ (95% CI:
371 US$–617 US$) and 749 US$ (95% CI: 679 US$–810 US$) for
cohort and catch-up vaccination respectively at 80% coverage.
Lowering the annual discount rate to emphasize present value to
society [44] would increase estimated maximum vaccine costs
(Fig. S7) from 176 US$ and 385 US$ to up to 480 US$ and 548 US
$ for cohort at 80% coverage and catch-up vaccination at 60% cov-
erage respectively under ‘Fast Track with PrEP’ assumptions.
Among the simulated vaccination strategies, catch-up vaccina-
tion age 18–35 is the most efficient when compared to cohort vac-
cination, since ART cost savings as well as averted DALYs are high,
despite very similar maximum vaccine cost. Sensitivity analyses
shows that maximum vaccine cost is proportional to the CET, e.g.
at a threshold of approximately 750$ per DALY averted (see Dis-
cussion for details), maximum vaccine cost would range between
22 US$ and 60 US$ under ‘Fast Track with PrEP’ assumptions and
74 US$ and 115 US$ in the ‘Status Quo without PrEP’ scenario
(Fig. S8).4. Discussion
The results of this study highlight the need to exploit different
vaccination targeting and roll-out scenarios to maximize the
population-level impact of a partially effective HIV vaccine in
South Africa. Even under high attrition rates, providing additional
booster doses for up to one decade after the primary series can
increase public health impact, as long as gender-specific age ranges
of highest incidence are covered by vaccination. Although adoles-
cent HIV vaccination has the potential of reaching high coverage
in South Africa through school-based programs (such as Human
Papilloma Virus routine vaccination [45]), our modeling results
(see Table 2 and Table S3) do not make a strong case for vaccinat-
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18 years of age [46]. The same conclusion applies to the potential
impact on vertical transmission by vaccinating 15-year-old
women. Prevention of mother-to-child transmission is efficacious
in South Africa (only 1.3% of live births in 2017 were HIV positive
[47]) and only 12% of live births are given at age 19 or younger
whereas 70% of births are given at ages 20–34 [48].
The time-dependent course of vaccine efficacy necessitates
aligning vaccination such that the times of highest efficacy are
within the ages of highest HIV incidence in 2027 – projected to
be 20–25 years of age for women, and five to ten years older for
men (Fig. S9). Specifically, our results indicate that, of the gen-
der/age combinations we compared, the greatest public health
impact of the pox-protein HIV vaccine would be achieved by vac-
cinating 18-year-old women and 23-year-old men.
Long-term economic evaluation of vaccination suffers, in part,
from the uncertainty of whether HIV treatment and prevention
scale-up could be achieved between now and 2027. We derived
estimates for the maximum vaccine cost (10-year regimen, includ-
ing product and delivery costs) to remain cost-effective averaging-
for two different treatment and prevention scale-up projections.
Our analysis suggested an estimated maximum cost of 105 US$–
787 US$ at which vaccination with a full 10-year regimen would
be cost-effective based on a 1xGDP per capita threshold [49]. Mea-
suring opportunity cost from a government perspective and deriv-
ing cost-effectiveness thresholds for health care interventions for
particular countries is an area of active research and debate [50].
Instead of using the WHO cost-effectiveness thresholds, the South
African HIV/TB investment case study group developed its own CE
threshold in determining the cost-effectiveness of new HIV inter-
ventions in South Africa. Using an iterative optimization approach
for all existing treatment and prevention options, the group con-
cluded that a cost-effectiveness threshold of approximately
750 US$ per life-year saved would be an appropriate upper bound
for the incremental cost to South Africa’s HIV program compared to
the baseline scenario (maintained coverage of all interventions at
2014 levels). This reflects the fact that HIV treatment and preven-
tion uptake is already saturated in South Africa, and suggests that
only a limited number of interventions should be scaled up to
avoid detrimental population health outcomes resulting from bud-
get funds being displaced from other interventions.
There are several major limitations to this analysis. The time-
dependent vaccine efficacy curves are based on limited data from
RV144 and goals for the pox-protein vaccine regimen, and we
did not consider any primary series attrition. Additional sources
of uncertainty include differences in regimens and study popula-
tions between RV144 and the ongoing trial, statistical uncertainty
in the RV144 results, and translation of cohort efficacy data to an
individual-based model in the absence of HIV exposure informa-
tion for the cohort under study. We did not model the impact of
possible changes in voluntary medical male circumcision scale-
up on vaccination, nor did we model the recently added 18-
month dose in the amended trial protocol. Since available data
on the distribution of earnings, non-healthcare consumption costs,
and patient time costs in South Africa were insufficient to be
included in this analysis, we adopted a government payer instead
of a societal perspective. The economic evaluation of the vaccine
does not account for indirect economic implications (e.g. produc-
tivity effects). The threshold analysis to determine the maximum
cost-effective cost per vaccine regimen included product, delivery
and implementation cost, which may vary across the simulated
strategies, making cost comparisons difficult. Although the esti-
mated maximum vaccine cost accounts for possible resource dis-
placement (e.g. ART cost saving), further additional investment
might be necessary to maintain treatment and prevention pro-
grams with concurrent vaccine roll-out, such that vaccine cost islikely underestimated. The lack of bounds on the vaccine price
and insufficient data on other cost-drivers such as staff training,
information campaigns and monitoring for such a complex regi-
men made it challenging to carry out a well-informed cost break-
down analysis. Furthermore, different target populations may be
more or less challenging to reach. This is difficult to know a priori
and was not included in the analysis, and therefore remains an area
important to explore in close collaboration with implementers of
HIV prevention programs. We did not model risk compensation
[15,51] i.e. increases in risky behavior by vaccine recipients, bear-
ing in mind that a partially effective vaccine might necessitate
additional counseling to prevent the false impression of full protec-
tion. Vaccine-induced seropositivity [52] is likely to add substan-
tial additional cost [53] due to the need to use nucleic acid based
HIV testing to distinguish HIV infections from the presence of
vaccine-induced HIV antibodies. Finally, we likely underestimate
the long-term benefits of vaccination. DALY calculations were
truncated at the vaccination endpoint in 2047, i.e. vaccination
could add at most 20 additional years of life from the start of vac-
cination to the endpoint.5. Conclusion
Taken together, our model suggests that, averaged across differ-
ent treatment scale-up settings, vaccinating population cohorts
aligned with the ages of highest HIV incidence (i.e. 18-year-old
women and 23-year-old men) including continued boosting for
up to 10 years could avert up to 13:1% and 11:5% of HIV infections
in the coming decades (for ‘Fast Track with PrEP’ and ‘Status Quo
without PrEP’ respectively). If durability of vaccine efficacy proves
to be better than observed in the RV144 trial, the benefit could be
appreciably larger. Adult catch-up vaccination and efforts to
ensure continued boosting, could further increase the impact of
the vaccination to possibly just over 18:3% (or 694;000) and
15:5% (or 935;000) of new infections prevented (for ‘Fast Track
with PrEP’ and ‘Status Quo without PrEP’ respectively). However,
we recognize that identifying optimal vaccine implementation
platforms and deployment channels to deliver this complex vac-
cine regimen at high coverage will be a significant challenge–espe-
cially when vaccinating 18 year-old women instead of adolescent
girls who may be more easily reached through a school-based pro-
gram. Therefore, improving deployability of HIV vaccine regimen
by optimizing vaccine performance characteristics (e.g. increased
vaccine efficacy, longer duration of protection, fewer required
doses) should be ultimate goal of future vaccine research. Hope-
fully, such optimization would be supported by the identification
of immune correlates of protection in HVTN 702. Although the
maximal impact of 18:3% of new infection prevented is apprecia-
ble, the roll-out of a partially effective, rapidly waning vaccine
alone will not eliminate HIV as a public health priority in South
Africa. Therefore, vaccination should be performed in parallel with
continued innovation in HIV prevention technologies.Author contributions
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